TR-1: Standard form for notification of major holdings
+------------------------------------------------------------------------------+ |NOTIFICATION OF MAJOR HOLDINGS | +------------------------------------------------------------------------------+
+---------------------------------+--------------------------------------------+ |1a. Identity of the issuer or the| | |underlying issuer of existing | Summit Therapeutics PLC | |shares to which voting rights are| Sedol BN40HZ0 | |attached(ii): | | +---------------------------------+--------------------------------------------+ |1b. Please indicate if the issuer is a non-UK issuer (please mark with an 'X'| |if appropriate) | +--------------------------------------------------------------+---------------+ |Non-UK issuer | | +--------------------------------------------------------------+---------------+ |2. Reason for the notification (please mark the appropriate box or boxes with | |an 'X') | +--------------------------------------------------------------+---------------+ |An acquisition or disposal of voting rights | X | +--------------------------------------------------------------+---------------+ |An acquisition or disposal of financial instruments | | +--------------------------------------------------------------+---------------+ |An event changing the breakdown of voting rights | | +--------------------------------------------------------------+---------------+ |Other (please specify)(iii): Participation in placing | X | +--------------------------------------------------------------+---------------+ |3. Details of person subject to the notification obligation(iv) | +---------------------------------+--------------------------------------------+ | |(1)Lansdowne Partners International Limited | | | | |Name |(2)Lansdowne Partners Limited | | | | | |(3)Lansdowne Partners (UK) LLP | +---------------------------------+--------------------------------------------+ |City and country of registered |London, United Kingdom | |office (if applicable) | | +---------------------------------+--------------------------------------------+ |4. Full name of shareholder(s) (if different from 3.)(v) | +---------------------------------+--------------------------------------------+ | | | | |HSBC Client Holdings Nominee (UK) Ltd, | |Name |HSBC Bank Plc Lansdowne Markets | | | | | |(Registered Shareholders) | | | | +---------------------------------+--------------------------------------------+ |City and country of registered |n/a | |office (if applicable) | | +---------------------------------+--------------------------------------------+ |5. Date on which the threshold |19/09/2017 | |was crossed or reached(vi): | | +---------------------------------+--------------------------------------------+ |6. Date on which issuer notified |20/09/2017 | |(DD/MM/YYYY): | | +---------------------------------+--------------------------------------------+ |7. Total positions of person(s) subject to the notification obligation | +------------------+-------------+----------------+-----------+----------------+ | | % of voting | % of voting | | | | | rights | rights through | Total of |Total number of | | | attached to | financial | both in % |voting rights of| | |shares (total| instruments |(8.A + 8.B)|issuer(vii) | | | of 8. A) |(total of 8.B 1 | | | | | | + 8.B 2) | | | +------------------+-------------+----------------+-----------+----------------+ |Resulting | | | | | |situation on the | | | | | |date on which |15.75% |11.35% |27.11% |70,316,908 | |threshold was | | | | | |crossed or reached| | | | | +------------------+-------------+----------------+-----------+----------------+ |Position of | | | | | |previous |17.95% |7.53% |25.48% | | |notification (if | | | | | |applicable) | | | | | +------------------+-------------+----------------+-----------+----------------+
+------------------------------------------------------------------------------+ | | |8. Notified details of the resulting situation on the date on which the | |threshold was crossed or reached(viii) | +------------------------------------------------------------------------------+ |A: Voting rights attached to shares | +--------------+------------------------------+--------------------------------+ |Class/type of |Number of voting rights(ix) |% of voting rights | |shares +---------------+ +-----------------+--------------+ |ISIN code (if | Direct | Indirect | Direct | Indirect | |possible) | (Art 9 of | (Art 10 of | (Art 9 of | (Art 10 of | | | Directive | Directive | Directive | Directive | | | 2004/109/EC) |2004/109/EC) | 2004/109/EC) |2004/109/EC) | | | (DTR5.1) | (DTR5.2.1) | (DTR5.1) | (DTR5.2.1) | +--------------+---------------+--------------+-----------------+--------------+ |GB00BN40HZ01 | |11,077,170 | |15.75% | +--------------+---------------+--------------+-----------------+--------------+ | | | | | | +--------------+---------------+--------------+-----------------+--------------+ | | | | | | +--------------+---------------+--------------+-----------------+--------------+ |SUBTOTAL 8. A | 11,077,170 | 15.75% | +--------------+------------------------------+--------------------------------+
+------------------------------------------------------------------------------+ |B 1: Financial Instruments according to Art. 13(1)(a) of Directive | |2004/109/EC (DTR5.3.1.1 (a)) | +--------------+----------+-------------+-----------------------+--------------+ |Type of | |Exercise/ |Number of voting rights| | |financial |Expiration|Conversion |that may be acquired if|% of voting | |instrument |date(x) |Period(xi) |the instrument is |rights | | | | |exercised/converted. | | +--------------+----------+-------------+-----------------------+--------------+ |American | | | | | |Depositary |N/A |N/A |7,983,330 |11.35% | |Shares (ADS) | | | | | +--------------+----------+-------------+-----------------------+--------------+ |SUBTOTAL 8. B|7,983,330 |11.35% | |1 | | | +-------------+-----------------------+--------------+
+------------------------------------------------------------------------------+ |B 2: Financial Instruments with similar economic effect according to Art. | |13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | +------------+------------+------------+----------------+-------+--------------+ |Type of | |Exercise/ | |Number | | |financial |Expiration |Conversion |Physical or cash|of |% of voting | |instrument |date(x) |Period (xi) |settlement(xii) |voting |rights | | | | | |rights | | +------------+------------+------------+----------------+-------+--------------+ | | | | | | | +------------+------------+------------+----------------+-------+--------------+ | | | | | | | +------------+------------+------------+----------------+-------+--------------+ |SUBTOTAL 8.B.2 | | | +----------------+-------+--------------+
+------------------------------------------------------------------------------+ |9. Information in relation to the person subject to the notification | |obligation (please mark the | |applicable box with an 'X') | +--------------------------------------------------------------+---------------+ |Person subject to the notification obligation is not | | |controlled by any natural person or legal entity and does not | | |control any other undertaking(s) holding directly or | | |indirectly an interest in the (underlying) issuer(xiii) | | +--------------------------------------------------------------+---------------+ |Full chain of controlled undertakings through which the voting| | |rights and/or the | | |financial instruments are effectively held starting with the | X | |ultimate controlling natural person or legal entity(xiv | | |)(please add additional rows as necessary) | | +--------------------+----------------+-----------------+------+---------------+ | | | % of voting | | | | % of voting | rights through | | | | rights if it | financial | Total of both if it | | Name(xv) | equals or is |instruments if it| equals or is higher | | |higher than the | equals or is | than the notifiable | | | notifiable | higher than the | threshold | | | threshold | notifiable | | | | | threshold | | +--------------------+----------------+-----------------+----------------------+ |Lansdowne Partners | | | | |International | | |27.11% | |Limited | | | | +--------------------+----------------+-----------------+----------------------+ |Lansdowne Partners | | | | |Limited | | | | +--------------------+----------------+-----------------+----------------------+ |Lansdowne Partners | | |27.11% | |(UK) LLP | | | | +--------------------+----------------+-----------------+----------------------+
+------------------------------------------------------------------------------+ |10. In case of proxy voting, please identify: | +-------------------------------------+----------------------------------------+ |Name of the proxy holder | | +-------------------------------------+----------------------------------------+ |The number and % of voting rights | | |held | | +-------------------------------------+----------------------------------------+ |The date until which the voting | | |rights will be held | | +-------------------------------------+----------------------------------------+
+------------------------------------------------------------------------------+ |11. Additional information(xvi) | +------------------------------------------------------------------------------+ | | +------------------------------------------------------------------------------+
+---------------------+-------------------+ | Place of completion | London | +---------------------+-------------------+ | Date of completion | 20 September 2017 | +---------------------+-------------------+
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via GlobeNewswire
A0DKWDBN40HZ0R40
Copyright RTT News/dpa-AFX